Tyra Biosciences, Inc. (TYRA) Stock Forecast
TYRA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.73 / 5 from 15 analysts
- Price target
- $47.45 average of analyst targets
- Upside to target
- +156.2% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.66
- 52-week range
- $13.99 – $39.61
TYRA analyst ratings
15 analystsNumber of analysts at each rating.
TYRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TYRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.67 | −$0.76 | −$0.47 | −$0.50 | −33.0% | 14 |
| Current fiscal year (2026) | −$2.64 | −$2.85 | −$2.20 | −$2.01 | −31.2% | 14 |
| Next fiscal year (2027) | −$2.77 | −$3.36 | −$2.23 | −$2.64 | −5.1% | 14 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TYRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 12 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 12 |
TYRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TYRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.65 | −$0.65 | −$0.68 | −$0.67 | −$0.67 | +2.7% | 2 up · 0 down |
| Current fiscal year (2026) | −$2.55 | −$2.66 | −$2.67 | −$2.64 | −$2.64 | +3.4% | 4 up · 0 down |
| Next fiscal year (2027) | −$2.82 | −$2.95 | −$2.96 | −$2.77 | −$2.77 | −1.7% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TYRA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TYRA beat in 6 of 12.
What analysts expect from TYRA
15 analysts cover Tyra Biosciences; their consensus rating is strong buy (4.73 on a 1–5 scale, where 5 is a strong buy). The average price target is $47.45, 156.2% above the latest close of $18.52. Analysts expect earnings of −$2.64 per share for 2026, −31.2% from a year earlier. For 2027 the average estimate is −$2.77 per share. Tyra Biosciences beat the EPS estimate in 6 of the last 12 quarters.
Related: TYRA income statement, TYRA key metrics, TYRA chart. See the TYRA stock overview for the latest quote and news.
TYRA forecast FAQ
What is Tyra Biosciences's price target?
The average analyst price target for Tyra Biosciences is $47.45, 156.2% above the latest close of $18.52.
Is Tyra Biosciences a buy, hold or sell?
Of 15 analysts covering Tyra Biosciences, 12 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tyra Biosciences's EPS forecast?
Analysts forecast −$2.64 per share for 2026 (range −$2.85 to −$2.20); for 2027 the estimate is −$2.77.
When does Tyra Biosciences report earnings?
Tyra Biosciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.66.
Does Tyra Biosciences usually beat earnings estimates?
Tyra Biosciences reported EPS at or above the analyst estimate in 6 of the last 12 quarters.